文献速递区域麻醉与超声疼痛医学

原位水凝胶延长罗哌卡因外周神经阻滞:绵羊随机对照试验

Prolonging peripheral ropivacaine nerve block with an in situ-formed hydrogel carrier: randomized controlled trial in an ovine model.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-03

本研究在10只雌性绵羊中采用随机双盲两周期交叉设计,比较200 mg罗哌卡因-泊洛沙姆-海藻酸水凝胶(Rop-HG)与200 mg普通罗哌卡因溶液(Rop-C)超声引导坐骨神经注射的效果。Rop-HG将中位感觉阻滞从24小时延长至60小时、运动阻滞从16小时延长至60小时,并降低早期血浆峰浓度,但组织病理学显示更严重且持续存在的局部组织变性、坏死和炎症。

要点

  • Rop-HG使中位感觉阻滞从24小时延长至60小时,运动阻滞从16小时延长至60小时。
  • Rop-HG降低早期全身暴露:中位Cmax 558 nmol/L、Tmax 8小时,而Rop-C为5101 nmol/L、0.33小时。
  • Rop-HG组出现更严重且持续的局部组织变性、坏死和炎症,延长效应来源尚不明确。

核心结论

  • 超声引导下200 mg Rop-HG神经周围注射较200 mg普通罗哌卡因溶液显著延长坐骨神经阻滞临床持续时间并降低早期全身暴露。
  • 该制剂伴随严重的局部组织变性、坏死和炎症,尚不清楚延长效应来自持续药物释放还是局部组织毒性。
  • 临床转化前需进一步优化制剂。

研究设计与样本

  • 随机、盲法两周期交叉研究,10只雌性绵羊。
  • 超声引导坐骨神经注射200 mg罗哌卡因-泊洛沙姆-海藻酸水凝胶(Rop-HG)或200 mg普通罗哌卡因溶液(Rop-C)。
  • 采用标准化临床评分系统重复评估感觉和运动功能,测定血浆罗哌卡因浓度,并对坐骨神经及周围组织进行死后组织病理学评估。

主要发现

  • Rop-HG较Rop-C显著延长阻滞持续时间:中位(IQR)感觉阻滞从24小时(IQR 16-36)延长至60小时(IQR 60-72),中位运动阻滞从16小时(IQR 16-18)延长至60小时(IQR 36-72)。
  • 药代动力学:Rop-C早期峰值尖锐,中位Cmax 5101 nmol/L、中位Tmax 0.33小时;Rop-HG峰值较低且延迟,中位Cmax 558 nmol/L、中位Tmax 8小时。
  • 组织病理学显示Rop-HG处理肢体局部组织反应更明显且持续,特征为变性、坏死和炎症。

临床怎么用

  • Rop-HG可显著延长绵羊坐骨神经感觉和运动阻滞时间并降低早期血浆罗哌卡因峰浓度。
  • 但制剂相关局部组织变性、坏死和炎症严重,临床转化前需优化配方并评估安全性。

局限性

  • 研究为绵羊模型,样本量10只,结果向人体外推需谨慎。
  • 尚不能区分延长阻滞效应来自持续药物释放还是局部组织毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local anesthetics are effective for regional anesthesia but have a relatively short duration of action. This motivates the development of sustained-release delivery systems. The aim of this study was to evaluate whether an in situ-forming hydrogel composed of poloxamers and alginate could prolong the duration of ropivacaine-induced sensory and motor blockade. METHODS: In this randomized and blinded two-period cross-over study, 10 female sheep received ultrasound-guided sciatic nerve injections of either 200 mg ropivacaine poloxamer-alginate hydrogel (Rop-HG) or 200 mg, as a control, plain ropivacaine solution (Rop-C). Sensory and motor functions were assessed repeatedly using a standardized clinical scoring system. Plasma ropivacaine concentrations were measured over time, and postmortem histopathological evaluation of the sciatic nerve and surrounding tissues was performed. RESULTS: Rop-HG markedly prolonged block duration compared with Rop-C, increasing the median (IQR) sensory block from 24 hours (IQR 16-36) to 60 hours (IQR 60-72) and the median motor block from 16 hours (IQR 16-18) to 60 hours (IQR 36-72). Pharmacokinetic analysis showed a sharp early peak for Rop-C (median Cmax 5101 nmol/L and median Tmax 0.33 hours), whereas Rop-HG produced a lower and delayed profile (median Cmax 558 nmol/L and median Tmax 8 hours). Histopathology revealed more pronounced and persistent local tissue reactions in Rop-HG-treated limbs, characterized by degeneration, necrosis, and inflammation. CONCLUSION: Ultrasound-guided perineural injections of 200 mg Rop-HG substantially prolonged the clinical duration of sciatic nerve block and reduced early systemic exposure compared with a 200 mg plain ropivacaine solution. However, the formulation was associated with severe local tissue degeneration, necrosis, and inflammation. Consequently, it remains unclear whether the prolonged clinical effect resulted from a sustained pharmacological release of ropivacaine or from the local tissue toxicity. Further optimization of the formulation is required before clinical translation.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Vingen HV, Ćuk A, Sauter AR, et al. Prolonging peripheral ropivacaine nerve block with an in situ-formed hydrogel carrier: randomized controlled trial in an ovine model. Reg Anesth Pain Med. 2026. PMID: 42692532. doi:10.1136/rapm-2026-108092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。